Since May 1, 2018, Norbert is President and CEO of Kronos Bio. Prior to joining Kronos, Norbert was at Gilead Sciences since 1990 and served as Executive Vice President for Research and Development from 2000 to 2018 and Chief Scientific Officer from 2007 to 2018. He was a Senior Scientist in Genentech’s DNA Synthesis Group from 1986 until 1990.
Norbert received a Ph.D. in organic chemistry from Zurich’s Eidgenössische Technische Hochschule and performed postdoctoral research in steroid chemistry at Syntex. He also performed additional research in organic chemistry and applied enzymology in Professor George Whiteside’s lab at Harvard University in Cambridge, Massachusetts. He has authored over 120 publications and is the inventor on 20 patents. Norbert serves on the Board of Directors for Bayer AG, InCarda Therapeutics and Kronos Bio.